Why BGPT?
logo

Assess an author's data and outputs

See the raw experimental evidence behind an author's publications and reproducibility signals.







Press Enter ↡ to solve



    Fuel Your Discoveries




     Quick Explanation



    Ariadne Androulidaki β€” scientific signal is currently low-to-moderate based on 2 papers and ~2 total citations (per your provided metrics). The most concrete evidence in the supplied data is a single mechanistic mouse/cell study linking peripheral CRF (via CRF1) to stress-driven breast tumor growth pathways (WNT/Ξ²-catenin, TGF-Ξ²/SMAD2), but key translational and reproducibility gaps remain (e.g., limited models, no public data accession).



     Long Explanation



    Author Review: Ariadne Androulidaki
    Science-strength critique (evidence-based, skeptical, biology-only). Date context: 2026-04-11.
    What we can verify from your supplied data
    • Bibliometric signal: 2 papers; total citations ~2; h-index 1 (values exactly as provided in your prompt; no external lookup was possible due to timeouts in your OpenAlex fetch attempt).
    • One fully described candidate paper: a 2010 mechanistic study in a mouse orthotopic 4T1 breast cancer model testing whether peripheral CRF mediates stress-enhanced tumor growth via CRF1 and downstream signaling.
    • Publication/data transparency: your extracted metadata states no public data accession numbers were provided.
    Paper-grounded evidence map (from the supplied full-text extract)
    Nodes/edges summarize the mechanistic pathway claims as extracted: stress β†’ peripheral CRF β†’ CRF1 β†’ WNT/Ξ²-catenin and TGF-Ξ²/SMAD2, plus cytoskeletal remodeling/migration, culminating in increased tumor growth/neoangiogenesis; peripheral antalarmin reduces these effects without changing stress corticosterone.
    Quantitative signal extracted: microarray ratios (Catnb, Smad2, Cdkn2a, etc.)
    From your extracted gene-ratio table (CRF 10^-8 M; timepoints 6h and 24h), below is a compact comparison of fold-change ratios for representative genes mentioned in the extract.
    Interpretation caution: these are ratios as extracted from a microarray panel and not necessarily equal to absolute biological effect sizes; they also represent only the subset of genes explicitly included in your extracted list. The extract also reports that CRF increased Ξ²-catenin and Smad2 trends at specific time windows (protein kinetics), so transcript/protein temporal alignment needs direct inspection in the paper figures.
    Strength of mechanistic claims (evidence vs uncertainties)
    What looks relatively strong (within this single paper)
    • Causal attempt via pharmacologic blockade: peripheral CRF1 antagonism (antalarmin) reportedly reduces stress-driven tumor/neoangiogenesis effects while corticosterone remains elevated, supporting a β€œperipheral mediator” claim rather than only global stress effects.
    • Multi-assay triangulation: the extract indicates concordant in vitro proliferation/migration phenotypes plus pathway evidence using reporter assays (WNT/TCF) and protein expression (Ξ²-catenin, SMAD2).
    Key limitations / blind spots (important for scientific strength)
    • Generalizability constraint: the extract’s limitations emphasize reliance on a single murine breast cancer model (4T1 in Balb/c) which may not represent diverse human tumor biology.
    • Data transparency: no public data accession numbers were stated, which weakens downstream verification/reuse.
    • Pathway specificity and alternative branches: the extract emphasizes CRF1, but also notes incomplete exploration of CRF2 roles in vivo; pathway causality would be stronger with direct genetic/orthogonal perturbations.
    • Angiogenesis quantification validation: the extract reports an in-house autofluorescence-based angiogenesis assessment without external validation, increasing measurement uncertainty.
    • Sample sizes: the extract states small group sizes for some assays (e.g., n=5 for corticosterone RIA), which can inflate false positive rates if effect sizes are modest or variability is high.
    Confidence level (based on supplied extract only): moderate for the existence of a stress→CRF1→tumor growth mechanistic chain in this specific mouse model; low-to-moderate for cross-model/translational claims.
    How this maps to the author’s scientific strength (given your metrics)
    This radar is not an author-wide career assessment (your dataset only details one paper). It translates the extract’s stated featuresβ€”multi-assay pathway links, pharmacologic mediation logic, but limited models, limited translational anchoring, and missing public data accessionβ€”into a 0–10 dimensional heuristic grounded in the cited paper.
    Critical bottleneck for judging author scientific strength: with only 2 total papers (per your provided metrics) and only one paper described here, the available basis for robust evaluation (replication track record, methodological evolution, breadth across topics/systems, and impact) is extremely limited.
    What would most disprove or change the main mechanistic claim?
    • Direct measurement showing that the relevant peripheral CRF species/concentration and CRF1 activation state in the tumor microenvironment does not rise during stress, or that antalarmin’s effects are mediated by off-target pathways rather than CRF1.
    • Orthogonal perturbations (e.g., CRF1 loss-of-function in tumor cells vs host tissues) yielding results inconsistent with the CRF1β†’WNT/Ξ²-catenin and CRF1β†’TGF-Ξ²/SMAD2 causal chain.
    • Replication in additional models/strains and with validated angiogenesis readouts producing inconsistent magnitude/direction of effects.
    These falsification routes follow the paper’s stated mechanism and identified limitations (e.g., model restriction, incomplete CRF2 exploration, in-house angiogenesis quantification, missing public data access).


    Feedback:   

    Updated: April 11, 2026

    BGPT Author Review



    Scientific Quality

    50%

    Based on the limited supplied evidence (2 papers total; only one paper described in detail), the scientific contribution shows mechanistic integration and multi-assay pathway logic (moderate strength). However, the current evaluable record is too small to infer consistent rigor across projects; the described study has typical translational/model limitations, incomplete pathway orthogonality (e.g., CRF2 not fully explored), and missing public data access, which reduces verifiability and generalizability. Overall: modest mechanistic competence, limited demonstrated breadth/impact.



    Communication Quality

    60%

    The provided information is largely from an extracted abstract/method/result summary; it does not include author-written narrative. From what is available, the study’s mechanistic claims appear structured (pathway β†’ phenotype β†’ rescue/antagonism), but this cannot be directly attributed to communication skill without full text.



    Author Novelty

    50%

    The general concept of stress signaling impacting cancer progression is established; the described contribution is a peripheral CRF/CRF1 mechanism with specific pathway wiring (WNT/Ξ²-catenin, TGF-Ξ²/SMAD2) in a particular model. That is potentially incremental/moderately novel rather than high novelty, based on the limited evidence provided.



    Scientific Rigor

    50%

    The extract shows multi-method corroboration (reporters, protein expression, microarray, in vivo phenotype, and an antagonism intervention), which supports internal rigor. But rigor is weakened by: limited model breadth, in-house angiogenesis quantification without external validation, some small sample sizes, and lack of public data accessβ€”hindering reproducibility and independent verification.

     Hypothesis Graveyard



    β€œStress enhances 4T1 tumor growth primarily by altering glucocorticoid (corticosterone) levels.” This is disfavored by the extract’s claim that antalarmin reduced tumor/neoangiogenesis effects without changing stress-induced corticosterone.


    β€œCRF acts through a VEGF-centric angiogenesis mechanism in this model.” This is weakened by the extract’s statement that VEGF was not detected after CRF, suggesting alternative angiogenic programs (e.g., Cox-2-linked) may dominate.

     Science Movie



    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion








    Get Ahead With Science Insights

    Custom summaries of the latest cutting edge Science research. Every Friday. No Ads.


    My BGPT